EP4724083A1 - Kombinationstherapie mit braf-hemmern zur behandlung von krebs - Google Patents

Kombinationstherapie mit braf-hemmern zur behandlung von krebs

Info

Publication number
EP4724083A1
EP4724083A1 EP24731928.8A EP24731928A EP4724083A1 EP 4724083 A1 EP4724083 A1 EP 4724083A1 EP 24731928 A EP24731928 A EP 24731928A EP 4724083 A1 EP4724083 A1 EP 4724083A1
Authority
EP
European Patent Office
Prior art keywords
cancer
seq
polypeptide
combination
braf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24731928.8A
Other languages
English (en)
French (fr)
Inventor
Mariano Federico ZACARIAS FLUCK
Jastrinjan KAUR
Laura Soucek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Publication of EP4724083A1 publication Critical patent/EP4724083A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP24731928.8A 2023-06-07 2024-06-06 Kombinationstherapie mit braf-hemmern zur behandlung von krebs Pending EP4724083A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23382554 2023-06-07
PCT/EP2024/065545 WO2024251854A1 (en) 2023-06-07 2024-06-06 Combination therapy with braf inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
EP4724083A1 true EP4724083A1 (de) 2026-04-15

Family

ID=86732645

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24731928.8A Pending EP4724083A1 (de) 2023-06-07 2024-06-06 Kombinationstherapie mit braf-hemmern zur behandlung von krebs

Country Status (7)

Country Link
EP (1) EP4724083A1 (de)
KR (1) KR20260020418A (de)
CN (1) CN121263199A (de)
AU (1) AU2024285758A1 (de)
IL (1) IL325025A (de)
TW (1) TW202502371A (de)
WO (1) WO2024251854A1 (de)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
EP0786522A2 (de) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatische RNA-Moleküle zur Behandlung von stenotischen Zuständen
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
DE69941447D1 (de) 1998-01-05 2009-11-05 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
ATE496944T1 (de) 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
MX2010005603A (es) 2007-11-26 2010-08-02 Bayer Schering Pharma Ag Anticuerpos antimesotelina y usos de los mismos.
WO2009080832A1 (en) 2007-12-26 2009-07-02 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
US9120854B2 (en) 2008-04-11 2015-09-01 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers
BR112013007160A2 (pt) 2010-09-29 2016-06-14 Philogen Spa ligante tiazolidina para a conjugação de fármacos a anticorpos
PE20141937A1 (es) 2011-11-16 2014-12-18 Amgen Inc Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2988786A4 (de) 2013-04-22 2016-12-21 Avelas Biosciences Inc Zusammensetzungen für selektive arzneiverabreichung und verfahren zur verwendung
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US10550190B2 (en) 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
WO2015183883A1 (en) * 2014-05-29 2015-12-03 Memorial Sloan Kettering Cancer Center Systems and methods for identifying drug combinations for reduced drug resistance in cancer treatment
KR102508023B1 (ko) 2014-09-03 2023-03-10 이뮤노젠 아이엔씨 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
WO2019018898A1 (en) 2017-07-28 2019-01-31 Phylogica Limited CELL PENETRATING PEPTIDES AND RELATED COMPOSITIONS AND METHODS
US20200164034A1 (en) * 2018-10-24 2020-05-28 Board Of Regents, The University Of Texas System Methods for improving sex-dimorphic responses to targeted therapy in melanoma
CN113795264A (zh) * 2019-03-19 2021-12-14 瓦尔希伯伦私人肿瘤研究基金会 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法

Also Published As

Publication number Publication date
IL325025A (en) 2026-01-01
WO2024251854A1 (en) 2024-12-12
TW202502371A (zh) 2025-01-16
AU2024285758A9 (en) 2026-01-15
CN121263199A (zh) 2026-01-02
KR20260020418A (ko) 2026-02-11
AU2024285758A1 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
AU2020242284B2 (en) Combination therapy for the treatment of cancer
CN115768458A (zh) CEBP-β拮抗剂的施用和使用方法
EP4473974A1 (de) Omomyc und kras-hemmern kombinationstherapie zur behandlung von krebs
EP4724083A1 (de) Kombinationstherapie mit braf-hemmern zur behandlung von krebs
EP4724100A1 (de) Kombinationstherapie mit mek-hemmern zur behandlung von krebs
WO2024089013A1 (en) Combination therapy for the treatment of cancer
EP2561885A2 (de) Verfahren für hades als tumorunterdrückungsziel
WO2007109908A1 (en) Therapeutic yb-1 phosphorylation decoys
WO2016141269A1 (en) Keratin 17 as a diagnostic and therapeutic target for cancer
EA046326B1 (ru) Комбинированная терапия для лечения рака
JP2021534826A (ja) がんの処置のためのペプチド治療薬およびその使用
JP2020147555A (ja) 抗がん剤抵抗性改善作用を有するクローディン−２結合性短鎖ペプチドの開発

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR